[
  {
    "ts": "2026-01-28T15:08:00+00:00",
    "headline": "Cardiovascular Surgical Devices Market Competitive Analysis Report 2025: Key Players, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts",
    "summary": "The cardiovascular surgical devices market is poised for growth, expected to rise from approximately $2.18 billion in 2025 to about $2.86 billion by 2033, at a 3.45% CAGR. Key factors driving this growth include increased cardiovascular disease rates, advances in surgical technology, and a shift towards minimally invasive procedures. Such developments are set to positively impact global cardiac healthcare. Prominent manufacturers, including Abbott, Boston Scientific, and Medtronic, continue to i",
    "url": "https://finance.yahoo.com/news/cardiovascular-surgical-devices-market-competitive-150800654.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "6311a9b0-ff4a-3108-88a3-9d000d5bbabb",
      "content": {
        "id": "6311a9b0-ff4a-3108-88a3-9d000d5bbabb",
        "contentType": "STORY",
        "title": "Cardiovascular Surgical Devices Market Competitive Analysis Report 2025: Key Players, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts",
        "description": "",
        "summary": "The cardiovascular surgical devices market is poised for growth, expected to rise from approximately $2.18 billion in 2025 to about $2.86 billion by 2033, at a 3.45% CAGR. Key factors driving this growth include increased cardiovascular disease rates, advances in surgical technology, and a shift towards minimally invasive procedures. Such developments are set to positively impact global cardiac healthcare. Prominent manufacturers, including Abbott, Boston Scientific, and Medtronic, continue to i",
        "pubDate": "2026-01-28T15:08:00Z",
        "displayTime": "2026-01-28T15:08:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/f1e2eb90728a62e0e92320b629a50ad9",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "Cardiovascular Surgical Devices Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ra7QvpL.Mdw2D1CML2F67w--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/f1e2eb90728a62e0e92320b629a50ad9.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vvBcH3VAhaNC199lAeQFYQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/f1e2eb90728a62e0e92320b629a50ad9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/cardiovascular-surgical-devices-market-competitive-150800654.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cardiovascular-surgical-devices-market-competitive-150800654.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABT"
            },
            {
              "symbol": "BSX"
            },
            {
              "symbol": "MDT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-28T14:51:39+00:00",
    "headline": "Abbot (ABT) is a High Quality Company, Says Jim Cramer",
    "summary": "We recently published 14 Stocks on Jim Cramer’s Radar. Abbott Laboratories (NYSE:ABT) is one of the stocks on Jim Cramer’s radar. Pharma giant Abbott Laboratories (NYSE:ABT)’s shares are down 15.9% over the past year and 12% year-to-date. The stock was dealt a hefty blow in January after the firm reported its fiscal fourth quarter earnings. […]",
    "url": "https://finance.yahoo.com/news/abbot-abt-high-quality-company-145139973.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "32d0582c-bc13-3cf7-945c-aee553af43c9",
      "content": {
        "id": "32d0582c-bc13-3cf7-945c-aee553af43c9",
        "contentType": "STORY",
        "title": "Abbot (ABT) is a High Quality Company, Says Jim Cramer",
        "description": "",
        "summary": "We recently published 14 Stocks on Jim Cramer’s Radar. Abbott Laboratories (NYSE:ABT) is one of the stocks on Jim Cramer’s radar. Pharma giant Abbott Laboratories (NYSE:ABT)’s shares are down 15.9% over the past year and 12% year-to-date. The stock was dealt a hefty blow in January after the firm reported its fiscal fourth quarter earnings. […]",
        "pubDate": "2026-01-28T14:51:39Z",
        "displayTime": "2026-01-28T14:51:39Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/a3355b66f8b9be42d814254460df8013",
          "originalWidth": 768,
          "originalHeight": 513,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rCTaHCgpGzUj4RF7k2iC1Q--~B/aD01MTM7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/a3355b66f8b9be42d814254460df8013.cf.webp",
              "width": 768,
              "height": 513,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/L27m5mMxNyq_f5F9HKD0oQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/a3355b66f8b9be42d814254460df8013.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbot-abt-high-quality-company-145139973.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbot-abt-high-quality-company-145139973.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-28T14:48:00+00:00",
    "headline": "Abbott Stock Fell the Most in 23 Years After Earnings. The CEO Bought $2 Million of Shares.",
    "summary": "Shares of  Abbott Laboratories  suffered their worst drop in more than 20 years following Abbott’s fourth-quarter earnings report.  A Form 4 filed with the Securities and Exchange Commission earlier this week shows CEO Robert Ford bought 18,800 shares for roughly $107.13 each, or $2 million in total, on Friday.  The shares are held in a family trust, of which Ford is a co-trustee, meaning he counts them among 216,203 shares he owns indirectly.",
    "url": "https://www.barrons.com/articles/abbott-stock-ceo-buys-2ea71f2a?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "8a779433-2271-35cd-a531-d5192d2f2770",
      "content": {
        "id": "8a779433-2271-35cd-a531-d5192d2f2770",
        "contentType": "STORY",
        "title": "Abbott Stock Fell the Most in 23 Years After Earnings. The CEO Bought $2 Million of Shares.",
        "description": "",
        "summary": "Shares of  Abbott Laboratories  suffered their worst drop in more than 20 years following Abbott’s fourth-quarter earnings report.  A Form 4 filed with the Securities and Exchange Commission earlier this week shows CEO Robert Ford bought 18,800 shares for roughly $107.13 each, or $2 million in total, on Friday.  The shares are held in a family trust, of which Ford is a co-trustee, meaning he counts them among 216,203 shares he owns indirectly.",
        "pubDate": "2026-01-28T14:48:00Z",
        "displayTime": "2026-01-28T14:48:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/8a779433-2271-35cd-a531-d5192d2f2770/abbott-stock-fell-the-most-in.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/47ebfdeca451e5e6247427d0ce21bb67",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ogMmDaPD7vko3t7KGv1vRw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/47ebfdeca451e5e6247427d0ce21bb67.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1HgZ3Le0IBONlzABm3Ufiw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/47ebfdeca451e5e6247427d0ce21bb67.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/abbott-stock-ceo-buys-2ea71f2a?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABT"
            },
            {
              "symbol": "F"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]